Anal carcinoma: Impact of TN category of disease on survival, disease relapse, and colostomy failure in US gastrointestinal intergroup RTOG 98-11 phase 3 trial

International Journal of Radiation Oncology Biology Physics

Volumn 87, Issue 4, 2013, Pages 638-645

  Gunderson, Leonard L ^a   Moughan, Jennifer ^b   Ajani, Jaffer A ^c   Pedersen, John E ^d   Winter, Kathryn A ^b   Benson III, Al B ^e   Thomas, Charles R ^f   Mayer, Robert J ^g   Haddock, Michael G ^h   Rich, Tyvin A ⁱ   Willett, Christopher G ^j  

^a MAYO CLINIC   (United States)

^b RADIATION THERAPY ONCOLOGY GROUP   (United States)

^c UNIVERSITY OF TEXAS   (United States)

^d CROSS CANCER INSTITUTE   (Canada)

^e NORTHWESTERN UNIVERSITY   (United States)

^f OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^g DANA FARBER CANCER INSTITUTE   (United States)

^h MAYO CLINIC CANCER CENTER   (United States)

ⁱ UNIVERSITY OF VIRGINIA   (United States)

^j DUKE UNIVERSITY   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

PATIENT MONITORING;

ANAL CANCER; CISPLATIN; CONCURRENT CHEMORADIATION; DISEASE FREE SURVIVAL; DISTANT METASTASIS; FLUOROURACIL (5-FU); GASTROINTESTINAL; MITOMYCIN; OVERALL SURVIVAL; REGIONAL FAILURES;

PATIENT TREATMENT;

CISPLATIN; FLUOROURACIL; MITOMYCIN;

ADULT; ANUS CARCINOMA; ARTICLE; BLOOD CHEMISTRY; CANCER COMBINATION CHEMOTHERAPY; CANCER INCIDENCE; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER SIZE; CANCER STAGING; CANCER SURVIVAL; CHEMORADIOTHERAPY; COLOSTOMY; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DISEASE FREE SURVIVAL; DISTANT METASTASIS; FOLLOW UP; HISTOPATHOLOGY; HUMAN; HYPOTHESIS; INDUCTION CHEMOTHERAPY; KARNOFSKY PERFORMANCE STATUS; MAJOR CLINICAL STUDY; MINIMAL RESIDUAL DISEASE; MULTIMODALITY CANCER THERAPY; NUCLEAR MAGNETIC RESONANCE IMAGING; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PHASE 3 CLINICAL TRIAL; PRIMARY TUMOR; PRIORITY JOURNAL; RANDOMIZATION; RECTOSCOPY; REGIONAL PERFUSION; SIGMOIDOSCOPY; THORAX RADIOGRAPHY; TREATMENT DURATION; TREATMENT FAILURE;

EID: 84886089467     PISSN: 03603016     EISSN: 1879355X     Source Type: Journal    
DOI: 10.1016/j.ijrobp.2013.07.035     Document Type: Article

References (26)

1. N.D. Nigro, H.G. Seydel, and B. Considine Combined preoperative radiation and chemotherapy for squamous cell carcinoma of the anal canal Cancer 51 1983 1826
2. B. Sischy, R.L. Doggett, and J.M. Krall Definitive irradiation and chemotherapy for radiosensitization in management of anal carcinoma: interim report on Radiation Therapy Oncology Group study 8314 J Natl Cancer Inst 81 1989 850 856
3. B.J. Cummings, T.H. Keane, and M.B. O'Sullivan Epidermoid anal cancer: treatment by radiation alone or by radiation and 5-fluorouracil with and without mitomycin C Int J Radiat Oncol Biol Phys 21 1991 1115 1125
4. M. Flam, M. John, and T.F. Pajak Role of mitomycin in combination with fluorouracil and radiotherapy, and salvage chemoradiation in the definitive nonsurgical treatment of epidermoid carcinoma of the anal canal: results of a phase III randomized intergroup study J Clin Oncol 14 1996 2527 2539
5. S.J. Arnott, D. Cunningham, and J. Gallagher Epidermoid anal cancer: results from the UKCCCR randomized trial for radiotherapy alone versus radiotherapy, 5-fluorouracil, and mitomycin Lancet 348 1996 1049 1054
6. H. Bartelink, F. Roelofsen, and F. Eschwege Concomitant radiotherapy and chemotherapy is superior to radiotherapy alone in the treatment of locally advanced anal cancer: results of a phase III randomized trial of the European Organization for Research and Treatment of Cancer Radiotherapy and Gastrointestinal Cooperative Groups J Clin Oncol 15 1997 2040 2049
7. J.A. Ajani, K.A. Winter, and L.L. Gunderson Fluorouracil, mitomycin and radiotherapy vs fluorouracil, cisplatin and radiotherapy for carcinoma of the anal canal: a randomized controlled trial JAMA 299 2008 1914 1921
8. L.L. Gunderson, K.A. Winter, and J.A. Ajani Long-term update of US GI Intergroup RTOG 98-11 Phase III trial for anal carcinoma: survival, relapse and colostomy failure with concurrent chemoradiation involving fluorouracil/ mitomycin versus fluorouracil/cisplatin J Clin Oncol 30 2012 4344 4351
9. J.A. Ajani, K.A. Winter, and L.L. Gunderson The US Intergroup anal carcinoma trial: combined analysis uncovers a pretreatment variable that predicts for colostomy J Clin Oncol 27 2009 1116 1121
10. J.A. Ajani, K.A. Winter, and L.L. Gunderson Reliable prognostic factors dictate clinical biology of anal cancer: an analysis of the prospective database of the intergroup trial RTOG 98-11 Cancer 116 2010 4007 4013
11. A. Allal, F.M. Laurencet, and M.A. Reymond Effectiveness of surgical salvage therapy for patients with locally uncontrolled anal carcinoma after sphincter conserving treatment Cancer 86 1999 405 409
12. E.L. Kaplan, and P. Meier Nonparametric estimation from incomplete observations J Stat Assoc 53 1958 457 481
13. N. Mantel Evaluation of survival data and two new rank order statistics arising in its consideration Cancer Chemother Rep 50 1966 163 170
14. J.D. Kalbfleisch, and R.L. Prentice The statistical analysis of failure time data 1980 John Wiley & Sons New York 167 169
15. R.J. Gray A class of K-samples test for comparing the cumulative incidence of a competing risk Ann Stat 16 1988 1141 1154
16. D.R. Cox Regression models and life-tables J R Stat Soc Series B Stat Methodol 34 1972 187 202
17. L.L. Gunderson, D.J. Sargent, and J.E. Tepper Impact of T and N stage and treatment on survival and relapse in adjuvant rectal cancer: a pooled analysis J Clin Oncol 22 2004 1785 1796
18. L.L. Gunderson, J.M. Jessup, D.J. Sargent AJCC Hindgut Taskforce Revised TN categorization for rectal cancer based on SEER and rectal pooled analysis outcomes J Clin Oncol 28 2010 256 263
19. L.L. Gunderson, J.M. Jessup, D.J. Sargent AJCC Hindgut Taskforce Revised TN categorization for colon cancer based on national survival outcome data J Clin Oncol 28 2010 264 271
20. P. Das, S. Bhatia, and C. Eng Predictors and patterns of recurrence after definitive chemoradiation for anal cancer Int J Radiat Oncol Biol Phys 68 2007 794 800
21. R. Glynne-Jones, and F. Lim Anal cancer: an examination of radiotherapy strategies Int J Rad Oncol Biol Phys 79 2011 1290 1301
22. D. Peiffert, L. Tournier-Rangeard, and J.P. Gerard Induction chemotherapy and dose intensification of the radiation boost in locally advanced anal canal carcinoma: final analysis of the randomized UNICANCER ACCORD 03 trial J Clin Oncol 30 2012 1941 1948
23. J.K. Schwarz, B.A. Siegel, and F. Dendashti Tumor response and survival predicted by post-therapy FDG-PET/CT in anal cancer Int J Radiat Oncol Biol Phys 71 2008 180 186
24. F.L. Day, E. Link, and S. Ngan FDG-PET metabolic response predicts outcomes in anal cancer managed with chemoradiotherapy Br J Cancer 105 2011 498 504
25. L. Kachnic, K. Winter, and R. Myerson RTOG 0529: A phase II evaluation of dose-painted intensity modulated radiation therapy in combination with 5-fluououracil and mitomycin-C for the reduction of acute morbidity in carcinoma of the anal canal Int J Radiat Oncol Biol Phys 86 2013 27 33
26. J.A. Ajani, X. Wang, and J.G. Izzo Molecular biomarkers correlate with disease-free survival in patients with anal canal carcinoma treated with chemo-radiation Dig Dis Sci 55 2010 1098 1105